{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Laboratory+Testing&page=46", "query": { "intervention": "Laboratory Testing", "page": 46 }, "page_size": 10 }, "pagination": { "page": 46, "page_size": 10, "total_count": 2412, "total_pages": 242, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Laboratory+Testing&page=47&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Laboratory+Testing&page=45&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T16:39:55.808Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01409993", "title": "Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Impaired Glucose Tolerance" ], "interventions": [ { "name": "Sildenafil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Hyperglycemic clamp", "type": "DIAGNOSTIC_TEST" }, { "name": "Euglycemic clamp", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2011-08", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01409993" }, { "nct_id": "NCT00742521", "title": "Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "glucose clamp", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 22, "start_date": "2001-03", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2015-06-10", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00742521" }, { "nct_id": "NCT00802204", "title": "Dopamine and Insulin Resistance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "PET scan", "type": "RADIATION" }, { "name": "Oral glucose tolerance test", "type": "PROCEDURE" }, { "name": "MRI", "type": "PROCEDURE" }, { "name": "Psychological scales to assess attitudes and behaviors related to eating and quality of life", "type": "BEHAVIORAL" }, { "name": "Caloric Restriction", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "BEHAVIORAL", "OTHER" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 28, "start_date": "2008-12", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2017-05-10", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00802204" }, { "nct_id": "NCT03934606", "title": "Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreas Cancer", "Prostate Cancer", "Hereditary Cancer", "Genetic Predisposition to Disease" ], "interventions": [ { "name": "Genetic testing for hereditary predisposition", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1488, "start_date": "2018-01-01", "completion_date": "2025-01-31", "has_results": false, "last_update_posted_date": "2025-04-10", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03934606" }, { "nct_id": "NCT02405247", "title": "TAURAS - T790 AURA ScreenFailure SOC Registry Study", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Patient Reported Outcome (PRO)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2015-06", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-07-31", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 2, "location_summary": "Oceanside, California • Santa Rosa, California", "locations": [ { "city": "Oceanside", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02405247" }, { "nct_id": "NCT02345265", "title": "Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Carcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Ovarian Carcinoma", "Ovarian High Grade Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal Carcinoma", "Primary Peritoneal Endometrioid Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 70, "start_date": "2016-05-23", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02345265" }, { "nct_id": "NCT04827563", "title": "Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma", "Shortness of Breath", "Dyspnea", "Cardiotoxicity" ], "interventions": [ { "name": "EndoPAT", "type": "DEVICE" }, { "name": "Blood Pressure Cuff", "type": "DEVICE" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "Quality of Life Assessment", "type": "OTHER" }, { "name": "Blood Tests", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-03-22", "completion_date": "2025-09-08", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04827563" }, { "nct_id": "NCT02823847", "title": "Non Invasive Oral Cancer Screening Among HIV Infected Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Malignant Neoplasms of Mesothelial and Soft Tissue", "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Screening Interview", "type": "BEHAVIORAL" }, { "name": "Carbon Monoxide Test", "type": "DEVICE" }, { "name": "Self-Help Materials", "type": "BEHAVIORAL" }, { "name": "Visual Oral Screening Examination", "type": "PROCEDURE" }, { "name": "Direct Fluorescent Oral Visualization Examination", "type": "PROCEDURE" }, { "name": "Oral Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "DEVICE", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2016-06-30", "completion_date": "2021-07-26", "has_results": false, "last_update_posted_date": "2022-02-14", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02823847" }, { "nct_id": "NCT04214067", "title": "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Endometrioid Adenocarcinoma", "Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 164, "start_date": "2020-04-09", "completion_date": "2027-02-05", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 275, "location_summary": "Birmingham, Alabama • Clovis, California • Concord, California + 195 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Clovis", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214067" }, { "nct_id": "NCT03063632", "title": "Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Myxoid Liposarcoma", "Metastatic Round Cell Liposarcoma", "Metastatic Synovial Sarcoma", "Recurrent Mycosis Fungoides and Sezary Syndrome", "Refractory Mycosis Fungoides and Sezary Syndrome", "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Unresectable Synovial Sarcoma" ], "interventions": [ { "name": "Interferon Gamma-1b", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 28, "start_date": "2017-12-14", "completion_date": "2023-03-14", "has_results": true, "last_update_posted_date": "2023-10-25", "last_synced_at": "2026-10-21T16:39:55.808Z", "location_count": 7, "location_summary": "Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03063632" } ] }